CD70 and PD‐L1 in anaplastic thyroid cancer – promising targets for immunotherapy

Aims During recent years, immune checkpoint inhibition has proved to be effective in several solid malignancies. The aim of this study was to identify novel targets for immunotherapy in anaplastic thyroid cancer by analysis of the expression of tumour antigens for which therapeutic agents are available. Method and results By immunohistochemistry we observed tumoral expression of CD 70 in 49% of cases. Expression of its receptor, CD 27, was present mainly in lymphocytes surrounding and infiltrating the tumour and observed only rarely in tumour cells. CD 70 expression was associated with the presence of a precursor papillary thyroid carcinoma and the presence of BRAF V600E mutations in the anaplastic thyroid cancer lesion. Furthermore, the expression of CD 70 seems stable during progression of the disease. Tumoral expression of programmed cell death ligand 1 ( PD ‐L1) was found in 28.6% of the anaplastic thyroid cancer cases. Programmed cell death 1 ( PD ‐1), the receptor of PD ‐L1, was not expressed on the tumour cells. No association between CD 70 expression and PD ‐L1 expression could be demonstrated. Conclusion These data suggest that targeted immunotherapy for CD 70/ CD 27 and PD ‐L1/ PD ‐1 might be promising in anaplastic thyroid cancer. However, as a low amount of tumour‐infiltrating lymphocytes was observed in most lesions, combined therapy with agents enhancing the invasion of lymphocytes in the tumour region needs to be considered.